CHEK2 and breast carcinoma: A study of 844 carriers of a CHEK2 PV found an average lifetime breast cancer risk close to the population level (14.3%) in the 20% of carriers with the lowest PRS and a high risk (32.6% lifetime risk) in the same proportion of women with the highest PRS.16